Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TP-03 ophthalmic solution for Demodex blepharitis
ISRCTN24398865Phase 2Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Nov 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lotilaner in Demodex blepharitis (DB), sponsored by Tarsus Pharmaceuticals, Inc. Primary endpoint: Signs of blepharitis measured using collarette grading at Day 42. Started Nov 2019; status: completed.
02
Drugs
lotilaner
03
Conditions
Demodex blepharitis (DB)
Beyond the preview
Go deeper on ISRCTN24398865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN24398865.